Boditech Med

Boditech Med is a prominent South Korean in vitro diagnostics company specializing in point-of-care testing (POCT) solutions. Founded in 1998, the company has established a global presence by developing high-sensitivity diagnostic platforms such as ichroma and AFIAS, which utilize fluorescence-based immunoassay technology. Their extensive product menu includes over 80 diagnostic markers for conditions ranging from cardiovascular disease and diabetes to cancer and infectious diseases. Boditech Med is dedicated to decentralizing healthcare by providing rapid, laboratory-quality results in various clinical settings. The company is publicly listed on the KOSDAQ and continues to expand its reach into therapeutic drug monitoring and molecular diagnostics. With a strong focus on research and development, Boditech Med serves healthcare providers in more than 120 countries.